News coverage about NuVasive (NASDAQ:NUVA) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuVasive earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 46.0021226965668 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

NUVA has been the topic of a number of recent research reports. Morgan Stanley reiterated an “equal weight” rating and set a $88.00 price target (up previously from $84.00) on shares of NuVasive in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and set a $90.00 price target on shares of NuVasive in a research note on Wednesday, July 5th. Cowen and Company reiterated an “outperform” rating and set a $90.00 price target (up previously from $85.00) on shares of NuVasive in a research note on Wednesday, June 28th. BidaskClub downgraded shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $76.00 price target on shares of NuVasive in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. NuVasive presently has a consensus rating of “Buy” and a consensus target price of $81.18.

Shares of NuVasive (NASDAQ NUVA) opened at 61.51 on Tuesday. The company has a market capitalization of $3.12 billion, a PE ratio of 96.87 and a beta of 1.06. NuVasive has a one year low of $56.70 and a one year high of $81.68. The firm’s 50-day moving average price is $70.61 and its 200 day moving average price is $73.61.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The business had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. During the same quarter last year, the business posted $0.40 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Analysts anticipate that NuVasive will post $2.00 earnings per share for the current year.

In other NuVasive news, EVP Peter Michael Leddy acquired 7,850 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was acquired at an average price of $63.88 per share, for a total transaction of $501,458.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Gregory T. Lucier acquired 5,000 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was acquired at an average price of $66.22 per share, with a total value of $331,100.00. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/nuvasive-nuva-given-coverage-optimism-score-of-0-18/1528939.html.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.